ERBB2 and breast carcinoma: The activity of trastuzumab in breast carcinomas overexpressing ERBB2 has contributed to the concept that certain tumours are ‘oncogene dependent’ (Weinstein, 2002; Baselga, 2006; Hengstler et al, 2006).